title: [Latrepirdine: a systematic review of the preclinical studies].
abstract: We conduct a systematic review of the preclinical studies published to date involving the use of latrepirdine (Dimebon ®). Latrepirdine is capable of modulating different targets, such as those related with mitochondria, acetylcholinesterase activity or intraneuronal calcium levels, perhaps thanks to its action upon the N-methyl-D-aspartate-type receptor, which belongs to the glutamate family. The findings published on the possible effect of latrepirdine in protein aggregation processes in disorders such as Alzheimer's disease and Parkinson's disease are quite controversial. Likewise, the possible neuroprotective effect of latrepirdine has been evaluated in animal models of neurodegenerative diseases, again with heterogeneous results. Consequently, it can be concluded that no preclinical scientific evidence has been found to justify carrying out clinical trials.
authors.forename: Nieves
authors.initials: N
authors.lastname: Cano-Cuenca
authors.forename: Julián
authors.initials: J
authors.lastname: Solís-García del Pozo
authors.affiliation: Universidad de Castilla La Mancha. Facultad de Medicina, 02006 Albacete, Espana.
authors.forename: Joaquín
authors.initials: J
authors.lastname: Jordán
mesh_terms: D000818:Animals; D001682:Biological Availability; D020013:Calcium Signaling / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D008928:Mitochondria / Q000187:drug effects; D015394:Molecular Structure; D009046:Motor Neurons / Q000187:drug effects; D019636:Neurodegenerative Diseases / Q000139:chemically induced / Q000188:drug therapy*; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000188:drug therapy; D066263:Protein Aggregation, Pathological / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014018:Tissue Distribution
chemical_list: D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D007211:Indoles; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; C010119:latrepirdine